Abstract
A double-blind, comparative and prospective study with nifedipine once a day was undertaken, in patients with mild and moderate high blood pressure. Blood pressure was measured by mercury sphygmomanometer in two positions: resting and sitting at 3, 6 and 12 weeks of treatment and by ambulatory blood pressure monitoring (ABPM) over 24 h; both were carried out before and after the treatment and the uniformity in the pressure levels were obtained by means of the Smoothness Index. Fifty-four patients were included in the trial, 28 in the microgranules group and 26 in the osmotic pump group. These groups were similar at the baseline in age, gender, weight, height, diastolic and systolic blood pressure. The nifedipine microgranules group had a heart rate higher than the nifedipine osmotic pump group at baseline (XM = 75.58 vs XB = 70.75). Blood pressure decreased significantly during the first 3 weeks; 85% in the microgranules group and 75% in the osmotic pump group reached a blood pressure ⩽140/90 mm Hg at the end of the study. Three patients in the microgranules group and two in the osmotic pump group required an additional antihypertensive drug. In both groups, the average blood pressure over 24 h was lowered without differences between groups. A decrease was induced in the heart rate in both groups which reached a marginal statistical significance in the microgranules nifedipine group. No changes were induced in the laboratory tests; two patients in the microgranules (8%) nifedipine group and five in the nifedipine osmotic pump group, adverse effects were observed, of which only one in each group required stopping the treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Guidelines Subcommittee 1999 World Health Organization-International Society of Hypertension. Guidelines for the Management of Hypertension J Hypertens 1999 17: 151–183
Brawnwald E . Mechanism of action of calcium-channel blocking agents N Engl J Med 1983 307: 1618–1627
Kaplan NM . Calcium entry blockers in the treatment of hypertension JAMA 1989 262: 817–823
Frishman WH, Charlap S, Michelson EL . Calcium-channel blockers in systemic hypertension Am JCardiol 1986 58: 157–160
Chung M, Reitberg DP, Gaffney M . Clinical pharmacokinetics of nifedipine gastrointestinal system: a controlled-release formulation of nifedipine Am J Med 1987 83 (Suppl 3): 10–14
Salazar A, Arocha I . Antihypertensive efficacy and tolerance of the osmotic formulation of nifedipine: Venezuelan Multicenter Study Acta Clinica (Bayer) 1993 4: 11–15
Scientific Technical Report of a new nifedipine to be administered every 24 hours Laboratorios Leti, Venezuela 1997
Coll Y, Rizzo A . Pharmacokinetics assessment of repeated doses of microgranules nifedipine 30 mg Tensomax ® Scientific Higher Board, Barcelona, Spain 1993
Waiters D et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis Circulation 1990 821: 940–953
Lichtlen PR et al on behalf of the INTAC GroupInvestigator. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTAC) Lancet 1990 335: 1109–1103
Collet H, Uzcategui I, Freites M, Gonzalez M . Efficacy and tolerance of a new nifedipine formulation to be administered once a day in the form of micro particles Arch Ven Farm Therap 1997 16: 78–81
Roa E et al. Blood pressure profiles in 24 hours inpatients with high blood pressure treated with two nifedipine formulations. Preliminary report TEMATICA 2000 1: 16–19
Ruilope L . New prospects in the treatment of artery hypertension (Results of the INSIGHT). Conference within the framework of the XIX South American Congress of Cardiology. Caracas, 9 June 2000
Schmieder R, Martus P, Klingbeil A . Reversal of left ventricular hypertrophy in essential hypertension JAMA 1996 275: 1507–1513
Yurenev AP, Dyakonova HG, Novkov ID . Management of essential hypertension inpatients with different degrees of left ventricular hypertrophy Am J Hypertens 1992 5: 5182–5189
Hansson L, Zanchetti A, Carruthers G, Dablof B . Effects of intensive blood pressure lowering and low dose aspirin inpatients with hypertension: principal result of the Hypertension Optimal Treatment (HOT) randomized trial Lancet 1998 351: 1755–1762
Frishman WH, Katz B . Controlled-release drugs delivery systems in cardiovascular disease treatment. In: Frishman WH, Sonmenblick ED (eds) Cardiovascular Pharmacotherapeutics McGraw Hill: New York 1997 1363–1374
White WB et al. Comparison of effects of controlled onset extended release verapamil at bedtime and nifidepine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate and the heart rate-blood pressure product Am J Cardiol 1998 81: 424–431
White WB . Analysis of ambulatory blood pressure data in antihypertensive drug trials J Hypertens 1991 21 (Suppl 1): S27–S32
Acknowledgements
The authors are grateful to Mrs Carmen Zulay Ibarra for her collaboration in performing the statistical analysis.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rodríguez-Roa, E., Octavio, A., Mayorca, E. et al. Blood pressure response in 24 hours in patients with high blood pressure treated with two nifedipine formulations once a day. J Hum Hypertens 16 (Suppl 1), S151–S155 (2002). https://doi.org/10.1038/sj.jhh.1001363
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001363